Aldosterone receptor antagonist and heart failure following acute myocardial infarction

Acta Cardiologica Sinica

Volumn 26, Issue 4, 2010, Pages 203-215

  Verma, Anil ^a   Bulwer, Bernard ^b   Dhawan, Ishita ^c   Yeh, Hung I ^d,e   Hung, Chung Lieh ^d,e,f  

^a OCHSNER MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HAVERFORD COLLEGE   (United States)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f NURSING AND MANAGEMENT COLLEGE   (Taiwan)

Author keywords

Acute myocardial infarction; Apoptosis; Heart failure; Renin angiotensin aldosterone system; Ventricular remodeling

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SPIRONOLACTONE;

ACUTE HEART INFARCTION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; HEART FAILURE; HUMAN; HYPERKALEMIA; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; REVIEW; RISK FACTOR;

EID: 79952857023     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Antman EM, Anbe DT, Armstrong PW, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:588-636.
2. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999;100:2054-9. (Pubitemid 29532055)
3. Haber E, George C. Griffith lecture. The role of renin in normal and pathological cardiovascular homeostasis. Circulation 1976; 54:849-61.
4. Pitt B, Zannad F, Remme WJ, et al. Randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
5. Pitt B, Remme W, Zannad F, et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med 2003;348:2271]. N Engl J Med 2003;348:1309-21.
6. Weber KT, Sun Y. Recruitable ACE and tissue repair in the infarcted heart. J Renin Angiotensin Aldosterone Syst 2000; 1:295-303.
7. Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone [Review]. Basic Res Cardiol 1993;88:107-24. (Pubitemid 23226442)
8. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112: e154-235.
9. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
10. Struthers AD. Aldosterone blockade in cardiovascular disease [Review]. Heart 2004;90:1229-34. (Pubitemid 39279920)
11. Lal A, Veinot JP, Ganten D, et al. Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. J Mol Cell Cardiol 2005;39:521-9. (Pubitemid 41133737)
12. Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodeling [Review]. Lancet 2006;367:356-67.
13. Delcayre C, Silvestre JS, Garnier A, et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000;57: 1346-51. (Pubitemid 30207889)
14. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701. (Pubitemid 29237459)
15. Hayashi M, Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001;38:1375-82. (Pubitemid 33033014)
16. Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006;114:2604-10. (Pubitemid 44967343)
17. Palmer BR, Pilbrow AP, Frampton CM, et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008;29:2489-96.
18. Hein S, Amon E, Kostin, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91. (Pubitemid 36258721)
19. Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141: 41-6. (Pubitemid 32061310)
20. Poulsen SH, Host NB, Jensen SE, et al. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000;101:1527-32. (Pubitemid 30180888)
21. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65. (Pubitemid 36628936)
22. Zannad F, Alla F, Dousset B, et al. RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000;102:2700-6.
23. Katada J, Meguro T, Saito H, et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 2005:111:2157-64. (Pubitemid 40632429)
24. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65. (Pubitemid 12203819)
25. Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-5. (Pubitemid 23067505)
26. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure [published correction appears in J Am Coll Cardiol 2002;39:746]. J Am Coll Cardiol 2002;39:70-8. (Pubitemid 34059863)
27. Tang WH, Parameswaran AC, Maroo AP, et al. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005;80:1623-30. (Pubitemid 41747065)
28. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-73. (Pubitemid 37378451)
29. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-8. (Pubitemid 34084645)
30. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101: 594-7. (Pubitemid 30094728)
31. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
32. Dyckner T, Wester PO, Widman L. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. Eur J Clin Pharmacol 1986;30:535-40. (Pubitemid 16073886)
33. Pitt B, Pitt GS. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation 2007;115:2976-82. (Pubitemid 46912101)
34. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006;97:4F-12F.
35. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005;46:1227-35. (Pubitemid 43189712)
36. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007;113:267-78. (Pubitemid 47372685)
37. Bunda S, Wang Y, Mitts TF, et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2009;284: 16633-47.
38. Pitt B, White H, Nicolau J, et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31. (Pubitemid 41040281)
39. Solomon SD, Zelenkofske S, McMurray JJV, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure or both. N Eng J Med 2005;352:2581-8. (Pubitemid 41007844)
40. Banas J, White H, Parkhomenko A, et al. Favorable outcomes with 25 mg of eplerenone in patients with post-AMI heart failure: results from the EPHESUS trial. J Cardiac Fail 2005;11:S156.
41. Pitt B, Ferrari R, Gheorghiade M, et al. Aldosterone blockade in post-acute myocardial infarction heart failure [Review]. Clin Cardiol 2006;29:434-8. (Pubitemid 44546932)
42. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005;111:1106-13. (Pubitemid 40365470)
43. Hohnloser SH, Kuck KH, Dorian P, et al. DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351: 2481-8. (Pubitemid 39603155)
44. Pitt B, Bakris G, Ruilope LM, et al. EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118:1643-50.
45. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. (Pubitemid 39025171)
46. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)